JP7751381B2 - Glp-2誘導体の持続型結合体 - Google Patents

Glp-2誘導体の持続型結合体

Info

Publication number
JP7751381B2
JP7751381B2 JP2020517828A JP2020517828A JP7751381B2 JP 7751381 B2 JP7751381 B2 JP 7751381B2 JP 2020517828 A JP2020517828 A JP 2020517828A JP 2020517828 A JP2020517828 A JP 2020517828A JP 7751381 B2 JP7751381 B2 JP 7751381B2
Authority
JP
Japan
Prior art keywords
glp
derivative
conjugate
group
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020517828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534840A (ja
JP2020534840A5 (cg-RX-API-DMAC7.html
Inventor
ジェヒョク チョイ
ミン ヨン キム
イン ヨン チョイ
スン ヨプ ジュン
Original Assignee
ハンミ ファーマシューティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハンミ ファーマシューティカル カンパニー リミテッド filed Critical ハンミ ファーマシューティカル カンパニー リミテッド
Publication of JP2020534840A publication Critical patent/JP2020534840A/ja
Priority to JP2023111438A priority Critical patent/JP2023138505A/ja
Publication of JP2020534840A5 publication Critical patent/JP2020534840A5/ja
Application granted granted Critical
Publication of JP7751381B2 publication Critical patent/JP7751381B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020517828A 2017-09-28 2018-09-28 Glp-2誘導体の持続型結合体 Active JP7751381B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023111438A JP2023138505A (ja) 2017-09-28 2023-07-06 Glp-2誘導体の持続型結合体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170126577 2017-09-28
KR10-2017-0126577 2017-09-28
PCT/KR2018/011586 WO2019066586A1 (ko) 2017-09-28 2018-09-28 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023111438A Division JP2023138505A (ja) 2017-09-28 2023-07-06 Glp-2誘導体の持続型結合体

Publications (3)

Publication Number Publication Date
JP2020534840A JP2020534840A (ja) 2020-12-03
JP2020534840A5 JP2020534840A5 (cg-RX-API-DMAC7.html) 2023-07-24
JP7751381B2 true JP7751381B2 (ja) 2025-10-08

Family

ID=65902619

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020517828A Active JP7751381B2 (ja) 2017-09-28 2018-09-28 Glp-2誘導体の持続型結合体
JP2023111438A Pending JP2023138505A (ja) 2017-09-28 2023-07-06 Glp-2誘導体の持続型結合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023111438A Pending JP2023138505A (ja) 2017-09-28 2023-07-06 Glp-2誘導体の持続型結合体

Country Status (22)

Country Link
US (3) US11530249B2 (cg-RX-API-DMAC7.html)
EP (1) EP3689898B1 (cg-RX-API-DMAC7.html)
JP (2) JP7751381B2 (cg-RX-API-DMAC7.html)
KR (2) KR102681143B1 (cg-RX-API-DMAC7.html)
CN (1) CN111433221B (cg-RX-API-DMAC7.html)
AR (1) AR113258A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018339210B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020006189A2 (cg-RX-API-DMAC7.html)
CA (1) CA3084326A1 (cg-RX-API-DMAC7.html)
DK (1) DK3689898T3 (cg-RX-API-DMAC7.html)
EA (1) EA202090571A1 (cg-RX-API-DMAC7.html)
ES (1) ES3075688T3 (cg-RX-API-DMAC7.html)
FI (1) FI3689898T3 (cg-RX-API-DMAC7.html)
IL (1) IL273528B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004453A (cg-RX-API-DMAC7.html)
PH (1) PH12020550105A1 (cg-RX-API-DMAC7.html)
PT (1) PT3689898T (cg-RX-API-DMAC7.html)
SA (1) SA520411644B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202002563WA (cg-RX-API-DMAC7.html)
TW (2) TWI794897B (cg-RX-API-DMAC7.html)
WO (1) WO2019066586A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202001888B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202111312UA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
EP4082561A4 (en) * 2019-12-24 2024-02-07 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating metabolic bone diseases, comprising glp-2 or conjugate thereof
US20230110689A1 (en) 2020-03-30 2023-04-13 Zealand Pharma A/S Agonist combination
CN115697375A (zh) * 2020-04-03 2023-02-03 韩美药品株式会社 预防或治疗放疗、化疗或其组合引发的粘膜炎的包含glp-2衍生物或其长效缀合物的药物组合物
IL298298A (en) 2020-05-22 2023-01-01 Hanmi Pharm Ind Co Ltd A liquid formulation of a long-acting conjugate of glp–2
CA3182260A1 (en) 2020-06-09 2021-12-16 Gleb Feldman Manufacture, formulation and dosing of apraglutide
CA3201916A1 (en) * 2020-12-24 2022-06-30 Hanmi Pharm. Co., Ltd. Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome
US20250276044A1 (en) * 2022-04-18 2025-09-04 Hanmi Pharm. Co., Ltd. COMBINATION THERAPY COMPRISING GLP-2, AND INSULINOTROPIC PEPTIDE, TNFa INHIBITOR, OR BOTH FOR PREVENTING OR TREATING BOWEL DISEASE
JP2026501948A (ja) 2022-12-23 2026-01-19 ハンミ ファーマシューティカル カンパニー リミテッド Glp-2誘導体又はその持続型結合体を含む移植片対宿主病の予防又は治療用薬学的組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532819A (ja) 2001-02-16 2004-10-28 コンジュケム,インコーポレーテッド 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド2(glp−2)
JP2015503554A (ja) 2011-12-30 2015-02-02 ハンミ サイエンス カンパニー リミテッドHanmi Scienceco.,Ltd. 免疫グロブリンフラグメントを用いた部位特異的glp−2薬物結合体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US20090238838A1 (en) * 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
ES2347902T3 (es) * 2004-04-23 2010-11-22 Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
DE602006020123D1 (de) * 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
KR101746686B1 (ko) * 2010-10-26 2017-06-15 한미사이언스 주식회사 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―2(glp―2)약물 결합체
ES2687651T3 (es) * 2011-09-12 2018-10-26 Amunix Operating Inc. Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532819A (ja) 2001-02-16 2004-10-28 コンジュケム,インコーポレーテッド 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド2(glp−2)
JP2015503554A (ja) 2011-12-30 2015-02-02 ハンミ サイエンス カンパニー リミテッドHanmi Scienceco.,Ltd. 免疫グロブリンフラグメントを用いた部位特異的glp−2薬物結合体

Also Published As

Publication number Publication date
US20230090790A1 (en) 2023-03-23
IL273528B2 (en) 2025-08-01
BR112020006189A2 (pt) 2020-10-13
US20200262888A1 (en) 2020-08-20
NZ762962A (en) 2024-07-05
ES3075688T3 (en) 2026-08-06
EP3689898A4 (en) 2021-06-16
AR113258A1 (es) 2020-03-11
CN111433221B (zh) 2024-12-27
EP3689898B1 (en) 2026-04-29
US20220251164A1 (en) 2022-08-11
TWI794897B (zh) 2023-03-01
PT3689898T (pt) 2026-07-16
FI3689898T3 (fi) 2026-07-21
KR102681144B1 (ko) 2024-07-04
KR20190037181A (ko) 2019-04-05
US12703730B2 (en) 2026-08-11
ZA202001888B (en) 2021-05-26
JP2020534840A (ja) 2020-12-03
AU2018339210B2 (en) 2023-02-02
SA520411644B1 (ar) 2024-02-25
TWI795443B (zh) 2023-03-11
IL273528B1 (en) 2025-04-01
TW202142560A (zh) 2021-11-16
EP3689898A1 (en) 2020-08-05
MX2020004453A (es) 2020-07-24
DK3689898T3 (da) 2026-07-27
KR102681143B1 (ko) 2024-07-04
KR20240013836A (ko) 2024-01-30
PH12020550105A1 (en) 2020-12-07
WO2019066586A1 (ko) 2019-04-04
US11530249B2 (en) 2022-12-20
AU2018339210A1 (en) 2020-04-16
TW201927806A (zh) 2019-07-16
CN111433221A (zh) 2020-07-17
JP2023138505A (ja) 2023-10-02
CA3084326A1 (en) 2019-04-04
SG11202002563WA (en) 2020-04-29
IL273528A (en) 2020-05-31
EA202090571A1 (ru) 2020-07-30

Similar Documents

Publication Publication Date Title
KR102681144B1 (ko) 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체
KR102413691B1 (ko) 신규한 인슐린 아날로그 및 이의 용도
KR102395856B1 (ko) 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도
KR101968344B1 (ko) 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
JP2022130723A (ja) グルカゴン、glp-1及びgip受容体のすべてに活性を有する三重活性体の持続型結合体
RU2733544C2 (ru) Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение
JP6336394B2 (ja) 生理活性ポリペプチド複合体の製造方法
JP6465817B2 (ja) インスリン位置特異的結合体
CN110536899A (zh) 对胰岛素受体具有降低的亲和力的胰岛素类似物复合物及其用途
KR101746686B1 (ko) 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―2(glp―2)약물 결합체
JP2023538236A (ja) グルカゴン、glp-1及びgip受容体の全てに対して活性を有する三重活性体を含む血圧降下用薬学組成物
EA047924B1 (ru) Конъюгаты производных glp-2 пролонгированного действия
HK40024582A (en) Long-acting conjugate of glucagon-like peptide-2 (glp-2) derivative
JP2026084695A (ja) グルカゴン、glp-1及びgip三重活性体の持続型結合体の液状製剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210927

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230306

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230706

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230712

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250926

R150 Certificate of patent or registration of utility model

Ref document number: 7751381

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150